MedTrace Logo

ICS/LABA Adherence and COPD Exacerbation

NCT02446041 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2016-10-11

No results posted yet for this study

Summary

The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD patients who are adherent to the index medication and those who are non-adherent.

Conditions

  • Pulmonary Disease
  • Chronic Obstructive

Interventions

OTHER

Non-Interventional Study

Non-Interventional Study

Sponsors & Collaborators

  • Carelon Research

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Frank Trudo, MD · AstraZeneca

Eligibility

Min Age
40 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02446041 on ClinicalTrials.gov